Immunohistochemical methods were used to search for Fas receptor/Fas ligand system involvement in multiple sclerosis (MS) white matter brain lesions. We found large numbers of Fas ligand (Fas-L)-bearing cells present in two acute lesions and 12 of 16 chronic MS lesions, and very few positive cells in non-inflammatory controls. Four of six brains from non-MS neuropathologic conditions associated with inflammation and white matter disease were, however, also positive for Fas-L. Double staining with cell-specific markers revealed that the pattern of ligand-positive cells in chronic MS lesions was complex and composed of several different cell types which were primarily resident glial cells with a small overlay ofmacrophages. Fas/APO 1 (CD95) receptor expression in MS tissue was also evaluated and marked upregulation of the receptor was found. In addition, Fas receptor was induced, but to a lesser extent, in numerous control brains. The observations that TUNEL-positive dying cells were present in MS lesions and showed excellent co-localization with Fas-L, indicate that the Fas death system may contribute to plaque pathogenesis and could lead to the development of a new category of therapeutic agents for MS.
M
ultiple sclerosis (MS) 1 is a common inflammatory disease of central nervous system white matter. It is considered to be an autoimmune condition, but the underlying mechanisms of tissue injury and cell death are poorly understood (1) . Possible mechanisms of cytotoxicity in human MS brain and the animal model, experimental allergic encephalomyelitis (EAE), have been studied for decades and several candidate death effectors have been proposed (2, 3) . In recent years, bursts of T cell-inflammatory cytokine production before and coincident with exacerbations of clinical disease have been widely implicated as effectors of tissue injury in both MS and EAE (4, 5) . We have recently used the in situ TUNEL assay for fragmented DNA to demonstrate that MS lesions often have substantial populations of inflammatory and resident glial cells undergoing cell death. Immunohistochemical identification of the dying cells with glial-specific marker co-labeling showed that 14-40% were the myelin-sustaining oligodendroglial cell and the pattern of electrophoresed DNA from some TUNELpositive MS brains also displayed laddering characteristic of apoptotic DNA cleavage (6) .
1Abbreviations used in this paper: EAE, experimental allergic encephalomyelitis; GFAP, glial fibrillary acidic protein; HNK, human NK marker; MS, multiple sclerosis.
In this study, we provide the first evidence implicating the newly identified Fas/Apo 1 (CD95) receptor/Fas ligand (Fas-L) cell death pathway in MS lesion pathogenesis. We show that Fas-L is widely present on glial cells in many chronic MS plaques and that white matter cells commonly carry receptors for this cytotoxin, rendering them sensitive to attack as judged by DNA fragmentation studies and Fas-L co-localization.
Materials and Methods

Autopsy Specimens
The study was performed on chronic MS plaques (n = 15) and control brains obtained from the Rocky Mountain Multiple Sclerosis Center (Englewood, CO), the MS human neurospecimen bank (West Los Angeles, CA) and from material collected over the past 23 yr at St. Vincent' s Hospital (New York, NY). Two paraffin-embedded acute MS plaques obtained from Dr. John Prineas (Newark, NJ) were also studied. The average post-mortem interval for MS paraffin-embedded material was 17.8 h and 5 were obtained within 7 h of death. The paraffin-embedded non-MS control brains included two ALS patients whose autopsies were performed within 3-6 h of death, HIV/AIDS encephalitis-2, Alzheimer's disease-I, cerebrovascular disease-i, Parkinson's disease-l, progressive multifocal leucoencephalopathy (PML)-I, acute hemorrhagic leucoencephalitis (AHLE)-I, glioblastoma multiformed tumor-l, and a child's brain with chronic measles virus infection, subacute sclerosing panencephalitis (SSPE)-I.
Immunohistochemistry for Fas Ligand, Fas Receptor, and In
Fas-L Detection. 3-b~m paraffin embedded sections were attached to slides precoated with vectorbond adhesive and dewaxed. Endogenous peroxidase activity was blocked by washing with 3% hydrogen peroxide for 5 rain and antigenic sites were exposed by immersion in target unmasking fluid (TUF; Signet Labs, Deedham, MA) preheated to 95~ for 10 min. The slides were removed from the water bath and allowed to remain in the heated TUF solution for an additional 10 rain. The slides were washed with PBS for 5 min • and incubated overnight at 4~ with polyclonal anti-human Fas-L antibody at 0.5 btg/ml (Q20-Santa Cruz Biotechnology, CA). The slides were again washed with PBS for 5 min • and antibody-positive cells were visualized with diaminobenzidine after reaction with the Vector ABC detection kit following the manufacturer's instructions. Slides on which the primary antibody was omitted were used to control for non-specific binding. As a further test of specificity, lymph node tissue sections were tested with Fas-L antisera, and virtually all cells were completely negative with positive cells being restricted to small intensely stained clusters within the nodal parenchyma.
The staining pattern obtained with Fas receptor antibody was also largely negative, except for a thin rim of positive cells which were localized to the lymph node subcapsular region. As an additional negative control, tissue sections from one of the non-inflammatory neurologic control brains which had no positive staining cells was routinely included in each experiment.
Fas/APO 1 (CD95) Receptor Detection. The slides for Fas/APO1
receptor detection were processed exactly as described for Fas-L except that a mouse monoclonal anti-human Fas receptor antibody at 10 I.tg/ml was used as the primary antibody (Oncor, Inc., Bethesda, MD).
In Situ TUNEL Detection. We used a modification of the TUNEL procedure (7) in which cells containing fragmented DNA are labeled with digoxigenin-11-dUTP and subsequently detected by an immunoperoxidase localization system. The in situ experiments were performed using kits purchased from Oncor (ApopTag kit) with minor modifications to the manufacturer's directions and no counterstain was usually employed. When testing 3-b~m-thick paraffin-embedded sections, we greatly curtailed the suggested deproteinization times with proteinase K (0-10 rain) and reduced the terminal deoxynucleotidyl transferase (TdT) incubation time from the suggested 60 rain to a range of 3-60 rain. FITC-fluorescent TUNEL labeling was used in several co-localization experiments and these sections were evaluated by confocal microscopy. For these experiments, the Fas-L second label was visualized with a Cy3 anti-rabbit detection system.
Double Staining
Immunohistochemistry. The ABC system was used for glial cell marker immunocytochemistry following the Fas-L detection procedure and visualization of the Fas reaction products with diaminobenzidine. Monoclonal primary antibody against astrocyte-specificc glial fibrillary acidic protein (GFAP); dilution 1:300, undiluted Human NK marker (HNK-1) (BectonDickinson, Mountain View, CA) against oligodendroglia, and CD-3 pan T cell marker; dilution 1:1,200 (all from Dako Corp., Carpenteria, CA) was applied overnight at 4~ The slides were rinsed and incubated for 30 rain with biotinylated secondary antibody and the procedure repeated with peroxidase-conjugated avidin-biotin complex (Elite Peroxidase ABC kit; Vector Labs., Inc., Burlingame, CA). Reaction product on double-labeled cells was visualized with Vector SG chromagen. The monocyte lineage-specific RCA-1 biotinylated lectin probe; dilution 1:1500 (Vector Labs.) was reacted for 1 h and reactions in the absence of primary antibody were used to control for nonspecific binding. Fas ligand-labeled cells were quantified by two observers by light microscopy and video projection using a 24-mm eyepiece disk reticle (5 • 5 mm in 1-mm subdivisions) calibrated with a stage micrometer. 10 fields (0.1 mm 2) from areas with maximal signal were quantified at 20• magnification. The number of Fas-L-bearing cells in the MS group was compared to the two control groups by the Kruskal-Wallis one way analysis of variance and the Mann Whitney U test. For double labeled cells, an average of 138 cells labeled for each glial-specific marker were scored for presence of the second (Fas ligand) label and expressed as a percentage of the total number counted.
Results
Quantification of Fas-L in MS Plaques. W e first investigated
whether or not Fas-L could be detected in sections from chronic plaques of MS white matter and from n o n -M S control brains by immunohistochemistry. Fig. 1 shows that of 16 chronic MS plaques tested 12 lesions had m a n y more cells reacting with Fas-L antibody than control brains from neurologic conditions without inflammation where 4 of 5 brains were completely negative. Nerve cells served as an additional internal negative control for antibody specificity since they were consistently Fas-L negative in all brains tested.
Identification of Fas Ligand-positive Cells in MS Brain.
The identity of Fas-L-positive cells in chronic MS lesions was detemained by co-localization staining with markers specific for monocytic lineage (macrophage/microglia [lectin/R.CA 1]), astrocytes (GFAP), and oligodendroglia ( H N K 1). (Fig. 2, lower left and right) . to contain extensive T cell infiltrates, CD3 reactive cells were rarely found in chronic MS plaques and were detected in only two chronic MS brains.
The complex pattern characteristic of MS lesions was clearly not present in two of the inflammatory non-MS control brains where increased numbers of heavily labeled Fas-L cells were also present. The labeled cells were mainly of macrophage origin (>90%) in the white matter lesions from the child with chronic measles infection (SSPE) and the labeled cells in the adult PML brain could be readily distinguished from the MS pattern because Fas-L staining was largely restricted to white matter cells with viral inclusions (>90%). The pattern of Fas-L-positive cells in acute hemorrhagic encephalomyelitis, a primary demyelinating disease, was complex as seen in MS. These findings in three other conditions with demyelinating lesions suggest that the potential for involvement of the Fas death pathway is not restricted to MS and may be the preferred pathway of killing for other inflammatory diseases with white matter pathology.
Fas/Apo 1 (CD95) Receptor Expression in Diseased Brain.
We next investigated to what extent Fas/Apo 1 (CD95) receptor was expressed in MS brains and non-MS controls as judged by immunohistochemistry because the demonstration of Fas ligand without its cognate receptor being present in the diseased area of the brains would be difficult to interpret. Fig. 4 shows that remarkably large numbers of strongly reactive Fas receptor-positive cells including some with glial cell morphologic characteristics were present within an acute white matter MS lesion, and the edematous plaque also contained numerous phagocytic macrophages which had engulfed Fas-positive cells. The presence ofphagocytosed Fas-positive corpses in the MS lesion suggests that the Fas system is likely involved in the MS white matter pathologic process. Smaller numbers of strongly labeled Fas re- ceptor expressing cells were present in three of four chronic plaques tested and we also found extremely widespread expression of Fas receptor, albeit with lesser intensity, in many non-MS neuropathologic conditions of diverse etiology including malignant glioblastoma multiforme, Alzheimer's and Parkinson's disease, cerebrovascular disease, and chronic CNS infectious processes including HIV, measles infection (SSPE), and JC-papovavirus infection (PML). These findings on non-MS brains indicate that whereas Fas receptor has been reported to be constitutively absent or weakly expressed in normal mouse and human brain parenchyma (8), brain is readily induced to express this receptor by a variety of pathologic stimuli (9) . The Fas receptor upregulation we have detected in several of our non-MS brain controls has been previously reported (10) (11) (12) (13) .
Fas-L Co-localizes with TUNELopositive Cells in MS Brain. To examine the possibility that the Fas pathway contributes to cell killing in MS white matter, we first employed an FITC-immunofluorescent in situ TUNEL assay which detects low molecular weight fragmented D N A within dying cells. Slides from several TUNEL-positive chronic MS lesions were subsequently dual labeled with the Fas-L antiserum which was visualized with a Cy3 detection system. The slides were evaluated by laser scanning confocal microscopy and as shown in 
Discussion
Evidence is rapidly accumulating that the Fas/Apo 1 (CD95)/Fas-L system is an important pathway responsible for the induction of cell death by apoptosis in homeostasis and disease states within several diverse tissues. Fas receptor (CD95) is a cell surface glycoprotein member of the tumor necrosis factor/nerve growth factor receptor superfamily and is widely expressed throughout the body (8, 9) . Fas receptor can be readily induced by cytokines such as TNF-~x and interferon-~ in some tissues including glial cells where it is not constitutively expressed (13, 14) . A cytoplasmic region called the "death domain" is present on the Fas receptor which shows strong homology with a similar domain on the TNF-tL l (15) . This highly conserved domain is necessary and sufficient for transduction of the apoptotic signal (16) .
The evidence to date indicates that Fas ligand, the other member of the pair, is much more restricted in its distribution and is constitutively expressed mainly in T cell-rich organs (17, 18) , stroma cells of the eye, and the testes (19, 20) . Fas-L expression can be upregulated in cytotoxic T cells, N K cells, and the TH1 subset of T helper cells. These activated T cells can generate both membrane bound and soluble forms of Fas-L (sFas-L) which in certain leukemia/lymphoma patients achieves measurable serum levels (21) . The patients with high levels of sFas-L are neutropenic and some have hepatic damage (22) . The Fas pathway is thought to be important in controlling the rapid turnover of mature neutrophils by apoptosis (23) . Several additional lines of evidence point to a role for accelerated Fas mediated destruction of liver tissue infected with hepatitis B or hepatitis C (24, 25) . The Fas receptor/Fas-L system also plays a critical homeostatic role in regulation of normal T cell deletion in the periphery as demonstrated in vivo by the enlarged lymphoid organs and enhanced lymphoproliferation present in lpr/lpr mutant mice which are defective in Fas receptor (26) (27) (28) (29) .
In this report, we present evidence that significant numbers of glial cells within MS plaques bear the cytotoxic effector molecule Fas-L. Of equal importance, ~30% of the positive cells belong to an HNK-l-positive oligodendroglial population. This glial cell is responsible for the production and support of myelin within the central nervous system. We also showed immunohistochemical evidence of widespread Fas receptor upregulation in the same MS lesions, indicating that both Fas death system components are available for interaction and possible Fas mediated cell destruction. The co-localization of TUNEL-positive dying cells with Fas-L, and the presence of numerous Fas-receptorpositive corpses within lesional macrophages support the notion that Fas receptor carrying cells are indeed a target of Fas-L attack in MS lesions.
The precise pathway for Fas signaling in brain white matter has not yet been studied. However, a recent report on Fas mediated apoptosis in mouse w4 transformed cells (which constitutively express mouse Fas receptor) found that Fas activation initially stimulates ICE-like proteases, and then CPP32-1ike proteases downstream to induce the morphologic changes and DNA fragmentation pattern typical of apoptosis (30) . This in vitro Fas-mediated process could be readily blocked by specific inhibitors of ICE and CPP32 family proteases indicating that if a role for Fas involvement and its pathway can be defined in MS, it may be possible to block the Fas-L-induced destruction by inhibition of the intracellular protease families mentioned above, solubilized Fas receptor, or other pharmacologic means.
